David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in other specialty areas including neurosciences, medical aesthetics and medical dermatology.
Mr. Pyott has driven the growth of Allergan by fueling internal development through significant investment in Research & Development while also identifying and leveraging unique, synergistic external opportunities. Allergan’s investment in Research & Development has increased from less than $100 million in 1998 to approximately $1 billion in 2013. Most notably, from an external perspective, in March 2006, Allergan acquired Inamed Corp. for over $3 billion to create the world’s largest medical aesthetics company. In 2007, Allergan acquired Groupe Laboratories Cornéal in France. Most recently, in December 2012, Allergan acquired SkinMedica, Inc. and is now the U.S. leader in the growing “physician dispensed” topical aesthetics category. In addition, in March 2013, Allergan acquired MAP Pharmaceuticals for almost $1 billion for its inhaled migraine therapy technology, cementing Allergan’s leadership in the U.S. migraine market.
In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. Mr. Pyott has also been recognized for his financial and leadership accomplishments by many prominent and well-respected business organizations. Mr. Pyott was recognized by Harvard Business Review as one of “The 100 Best CEOs in the World” in both 2009 (ranked #50) and 2013 (ranked #26) one of three pharmaceutical CEO’s, and was recognized as the “#1 CEO in Specialty Pharmaceuticals” by Institutional Investor magazine in 2005, 2007, and the “Best CEO Healthcare – Pharmaceuticals” in 2012 and 2013. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology.
Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, working over 17 years in several positions in strategic planning, marketing and general management around the world.
Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.
Mr. Pyott is a member of the Board of Directors of Avery Dennison Corporation and Edwards Lifesciences Corporation. He serves on the Board and as Chairman of the California Healthcare Institute, on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization, is Vice Chairman of the Board of Trustees of Chapman University, and on the Directors’ Board of The Paul Merage School of Business at the University of California Irvine.